chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Received Pfizer COVID vaccine 7/2/22. Her mother notes that she first saw the red bumps the next day. Per mom, got "insect bites" 2 weeks ago. A few days ago they flared up after going to a water park. They were near the diaper area - four of them swelled up.  She has had no fever, no illness over the past month.     She describes the rash that appeared 2 days ago had spreading redness with central pallor and a red raised circular redness that is itchy. The first ones on her lateral thighs improved after using hydrocortisone topically, but other ones the next day increased.
This spontaneous report as received from a nurse practitioner as part of a marketing research program, refers to a male patient of unknown age. Patient's concurrent conditions and relevant medical history was unknown. On an unknown date the patient was vaccinated with ZOSTAVAX (lot number, dose and route unspecified) for prevention of shingles. Concomitant medications were unknown. On an unknown date the patient and his wife came in together and stated that they both received ZOSTAVAX, however the patient still got shingles event after vaccination and both verbalized understanding. The outcome of the events was unknown. The causality of the events with ZOSTAVAX was not reported. Additional information is not expected.
FEVER; PROBLEMS WITH BREATHING; SUSPECTED COVID-19; FOETAL EXPOSURE DURING PREGNANCY; This solicited pregnancy report received from a consumer concerned a male neonate of an unspecified race and ethnicity. The patient was enrolled in a non-company sponsored study. The patient's weight was 3.51 kilograms, and height was not reported. No concurrent conditions were reported. The patient's mother medical history included asthma and polycystic ovary syndrome, multigravida. Maternal obstetrical history included two previous pregnancies, one resulting in miscarriage/ spontaneous abortion in less than 20 weeks and one in a live baby. The mother had no history of tobacco, e-cigarette and recreational drug use, and alcohol use. Maternal first day of the last menstrual period (LMP) was calculated to be 16-FEB-2021. The estimated delivery date (EDD) was reported to be 23-NOV-2021. Type of pregnancy was reported as singleton. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, transplacental, batch number: 1805022 expiry: UNKNOWN) dose was not reported, 1 total administered on 13-MAR-2021 (at gestational age three weeks and four days) for covid-19 immunisation. Concomitant medications included minerals nos/vitamins nos.  On 13-MAR-2021, the patient experienced foetal exposure during pregnancy. The duration for the event, foetal exposure during pregnancy was 255 days. at gestational age of 40 weeks, the patient's mother delivered a live, full-term, male neonate vaginally. The patient's mother's spent three days in hospital for the delivery. On 23-NOV-2021, the baby was admitted in NICU for fever and problems with breathing.  On NOV-2021, Laboratory data included: Cardiac function test (not reported), and Hearing test (not reported).  On 09-FEB-2022, the patient developed symptoms of COVID-19 (suspected covid-19): cough and fever of 101 Fahrenheit. On FEB-2022, Laboratory data included: Body temperature (not reported). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from fever, and problems with breathing on 25-NOV-2021, suspected covid-19 on 23-FEB-2022, and foetal exposure during pregnancy on 23-NOV-2021. The reporter considered the causality between covid-19 vaccine ad26.cov2.s, and fever, and problems with breathing as not related. The reporter did not provide a causality assessment between covid-19 vaccine ad26.cov2.s, and suspected covid-19, and foetal exposure during pregnancy. Company causality between covid-19 vaccine ad26.cov2.s, and suspected covid-19, and foetal exposure during pregnancy was not related.  This report was serious (Hospitalization Caused / Prolonged). This parent/child case is linked to 20211109970.; Sender's Comments: V0: 20230520946-Fever (Fever neonatal), problems with breathing. The event shows an incompatible temporal relationship. Therefore, this event is considered inconsistent with vaccine administration.
COVID-19; Chest discomfort; cough; Dizziness; mild fever that would come and go; extreme body chills; really bad pressure in my head that felt like my head was going to blow off; body aches that would just pop up anywhere on my body like someone hit me with a hammer; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID-19), PAIN (body aches that would just pop up anywhere on my body like someone hit me with a hammer), CHEST DISCOMFORT (Chest discomfort), COUGH (cough) and DIZZINESS (Dizziness) in a 60-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 22-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Mar-2021, the patient experienced PAIN (body aches that would just pop up anywhere on my body like someone hit me with a hammer), PYREXIA (mild fever that would come and go), CHILLS (extreme body chills) and HEADACHE (really bad pressure in my head that felt like my head was going to blow off). On 26-Mar-2021, the patient experienced CHEST DISCOMFORT (Chest discomfort), COUGH (cough) and DIZZINESS (Dizziness). On 29-Mar-2021, the patient experienced COVID-19 (COVID-19). On 24-Mar-2021, PAIN (body aches that would just pop up anywhere on my body like someone hit me with a hammer) and CHILLS (extreme body chills) had resolved. On 25-Mar-2021, PYREXIA (mild fever that would come and go) and HEADACHE (really bad pressure in my head that felt like my head was going to blow off) had resolved. At the time of the report, COVID-19 (COVID-19), CHEST DISCOMFORT (Chest discomfort) and COUGH (cough) outcome was unknown and DIZZINESS (Dizziness) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 29-Mar-2021, SARS-CoV-2 test: positive Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant product information was reported.  Treatment information include OTC cough syrup and throat spray (name not mentioned).
around one week post vaccination, I felt my left armpit lymph node swollen and painful.  The injection site also started to itch, then got red, inflamed and swollen.
wife had both doses in her 2nd trimester; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of EXPOSURE DURING PREGNANCY (wife had both doses in her 2nd trimester) in a 34-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 012L20A and 031L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 08-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. The patient's last menstrual period was on 30-Sep-2020 and the estimated date of delivery was 08-Jul-2021. On 08-Jan-2021, the patient experienced EXPOSURE DURING PREGNANCY (wife had both doses in her 2nd trimester). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  fourteenth week of the pregnancy.  On 05-Feb-2021, EXPOSURE DURING PREGNANCY (wife had both doses in her 2nd trimester) had resolved.            No concomitant medications reported.  No treatment medications provided by the reporter.
I experienced late periods which has never happened to me before, arrhythmia and severe headaches.
Left arm was very sore at injection site for four days.  I had a large lump on the arm at the injection site for four days.  Mild fatigue for   two days.
pt recvd vax & exp erythematous macular papular rash on palms;
Information has been received from a nurse concerning her 8 weeks grand daughter who on an unspecified date was vaccinated with the first 2ml dose of ROTATEQ. 3 days later the patient was doubled over, clearly pain, and screaming. The patient's mother called her mother, the nurse, for help. The patient's mother did not contact the patient's doctor or visit the emergency room. The nurse stated the patient experienced moderate reaction of intussusception. The patient's symptoms lasted for 24 hours and resolved itself. It was reported that the therapy with ROTATEQ was discontinued and was not reintroduced. Upon internal review, moderate reaction of intussusception was determined to be an other important medical event. Additional information has been requested.
Began around 3am (exact time unknown due to it being overnight while sleeping) Extreme chills (shaking, not just shivering) Fever (101.2 after waiting a couple of hours to take temperature) which didn't break for over 8 hours Nausea Dizziness Headache Symptoms didn't completely go away for 24 hours
Headache; Nausea; Muscle aches; Chills; Tiredness; Joint pain; Injection site pain; This is a spontaneous report from a contactable consumer, the patient. A 62-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153), via an unspecified route of administration in the left arm on 08Apr2021 at 12:00 (at the age of 62-years-old), as a single dose for COVID-19 immunisation. Medical history included blood pressure high, acid reflux and seasonal allergies. Concomitant medications included calcium citrate (CITRACAL), hydrochlorothiazide (MANUFACTURER UNKNOWN), losartan (MANUFACTURER UNKNOWN) and colecalciferol (VITAMIN D3); all from unknown dates for unknown indications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206), via an unspecified route of administration in the right arm on 21Mar2021 at 11:45 (at the age of 62-years-old), as a single dose for COVID-19 immunisation. The patient previously took erythromycin (MANUFACTURER UNKNOWN) and tetracycline (MANUFACTURER UNKNOWN); both on unknown dates for unspecified indications and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08Apr2021 at 15:00, the patient experienced headache, nausea, muscle aches, chills, tiredness, joint pain and injection site pain. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events of headache, nausea, muscle aches, chills, tiredness, joint pain and injection site pain were resolved on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
from top of ankle to all the way down to toe, I touch it and it hurts; tender; both ankles are extremely tender; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (from top of ankle to all the way down to toe), TENDERNESS, and ARTHRALGIA in a 51-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 043L20A) for COVID-19 vaccination.     Concurrent medical conditions included Guillain-Barre syndrome and Paralyzed (At young age).    On 22-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (from top of ankle to all the way down to toe), TENDERNESS, and ARTHRALGIA. The patient was treated with TYLENOL at an unspecified dose and frequency. At the time of the report, PAIN IN EXTREMITY (from top of ankle to all the way down to toe), TENDERNESS, and ARTHRALGIA had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       The patient received Tylenol but it did not help.
Rash-uncertain in description, appeared around nostrils this morning. Father uncertain if red or hives. Person at facility notified. Rash had subsided by mid-morning.
Extreme fatigue; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0176) via an unspecified route of administration in the right arm on 28Apr2021 at 15:00 (at the age of 41-year-old) as a single dose for COVID-19 immunisation. Medical history included depression, migraines and high blood pressure. The patient did not have any known allergies. Concomitant medications included escitalopram (MANUFACTURER UNKNOWN); bupropion (MANUFACTURER UNKNOWN); hydrochlorothiazide (MANUFACTURER UNKNOWN) and naloxone hydrochloride;buprenorphine hydrochloride (SUBOXONE); all for unknown indications from unknown dates and unknown if ongoing. The patient did not receive other vaccines within four weeks prior to the COVID vaccine. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EW0153) via an unspecified route of administration in the left arm on 07Apr2021 at 15:00 (at the age of 41-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 29Apr2021 at 09:00, the patient experienced extreme fatigue lasting four days post second COVID vaccine. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event extreme fatigue was resolved on an unknown date in 2021.  No follow-up attempts are needed. No further information is expected.
pt recv vax 26APR99 1130AM awoke during the noc w/crankiness;mom also noted red papular rash on face & neck morning of 27APR99-rash on trunk & extremities also;rash subsided by 30APR99;no fever;tx w/PRN PAPA;
Information has been received from a nurse referring to multiple unspecified patients of unknown ages and gender. On unknown dates the patients were vaccinated with doses of improperly stored VARIVAX (Lot# L027287, expiry 21-JUL-2017; strength, dosage, frequency and route unspecified). The vaccines were exposed to -2.6 degree C for 1 hours and 45 minutes. No previous excursions. Data logger was unspecified. No adverse effects were reported. No product quality complaint (PQC) was filled. This is one of several reports received from the same reporter. Additional information has been requested.
Patient states she started feeling like she had a fever around 4 pm. She took her temperature, which was 99.9 degrees F. She had no other symptoms or signs. She took some acetaminophen. She states she felt better shortly after and had no further feelings of fever.
Patient was given a moderna booster instead of a pfizer booster. She was too young for moderna booster, as she was only 16 at time of vaccination
Patient's wife reported that patient had a fever of 101.3 on Saturday and on his left arm there was a 4 in band going around his arm (width) site of administration, red and warm to touch. Pt took TYLENOL.
Accidentally received second dose, last dose given 09/19/2019.  No current s/s of any immediate reaction
This spontaneous report was received from a nurse practitioner via company representative and refers to a unspecified female patient with the age reported as "around the age of sixty five"). There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided.  On an unknown date, the patient was vaccinated with a dose of PNEUMOVAX23 for prophylaxis (also reported as "the appropriate age for the administration") (dose, route of administration, anatomical location lot# and expiration date were not reported).  According to the reporter, the vaccination resulted in an immediate local reaction described also as 'lots swelling at the insertion site". The outcome of the events was unknown. The relatedness between the vents and PNEUMOVAX23 was not reported. Additional information has been requested.
This spontaneous report as received from a health professional refers to a multiple unspecified patients of unknown ages and genders. Information regarding the patients' pertinent medical history, drug reactions/allergies and concomitant medications was not reported. On an unknown dates, the patients were vaccinated with improperly stored PROQUAD (Merck) (lot # L032761, expiration date 24-FEB-2017, dose and route of administration were not reported). No adverse effects reported. There was no product quality complaint. This is one of several reports received from the same reporter. Additional information has been requested.
10 days after receiving smallpox vaccination he woke up with substernal chest pain. Pain got worse 5/10 and he was transported to the hospital. Remained in the hospital for 3 days. Had ST elevations on his EKG and troponin level was elevated to 1.25
Large local reaction with possible associated cellulitis on right arm-deltoid. 4-5cm diameter redness started 48 hours after receiving shot and spread 24 later.
patients under 18 years old received a dose of the Moderna COVID19 vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (patients under 18 years old received a dose of the Moderna COVID19 vaccine) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 004c21a) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Nov-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-Nov-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (patients under 18 years old received a dose of the Moderna COVID19 vaccine). On 14-Nov-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (patients under 18 years old received a dose of the Moderna COVID19 vaccine) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter. Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 15-Nov-2021: Follow-up information included no new information
Fever, Fatigue, joint aches, muscle aches, Rapid heart beat, palpitations, weakness, Loss of appetite, headache, burning eyes, dizziness (@ site), red, hot to touch, pain, itching, swelling pain shooting down arm
Case hospitalized on 7/20/2021 for COVID.  Symptoms unknown - have been unable to reach case.
Initially it was reported by one nurse that the patient was seen by the doctor on 10/24/2000 with a cough and mild varicella-like rash over his trunk. In follow-up, another nurse reported that the patient developed varicella with mild to moderate amount of vesicles from 10/22/2000 lasting until 10/27/2000. The patient recovered 10/27/2000. Additional information has been requested.
Information has been received from a health care worker concerning unknown number of patients of unknown demographics. On unspecified dates, the patients were inadvertently vaccinated with improperly stored LIQUID PEDVAXHIBZ (dose, route, lot number and expiration date were unspecified). No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
93 y.o.    Admit Date:  7/24/2022   Discharge Date:   7/28/2022   Discharge Diagnosis:  Principal Problem:   Acute metabolic encephalopathy Active Problems:   COVID-19 virus infection   Closed left ankle fracture   Falls frequently   Dementia   HTN (hypertension)     Hospital Course:  93 year old female resident of assisted living facility was admitted after she fell and suffered from distal tibia and fibula fractures in the left ankle. She was splinted and placed on cast. She also was treated for Covid-19 infection with Remdesivir. She has been on Lovenox and will be continued after discharge due to elevated d dimer. She has been accepted at a rehab facility and will be transferred today. Follow up with ortho.   Physical Exam on the day of discharge: Last Recorded Vital Signs: Temp: 98.1 °F (36.7 °C) Pulse: 85 BP: 131/83 Respirations: 18 SpO2: 95 % O2 Flow Rate (l/min): 0 l/min     Consults:  IP CONSULT TO SOCIAL WORK   Significant Diagnostic Studies:   BLE venous US, CTA chest   Operations: none   Disposition:  Nursing facility   Discharge Condition:  Fair    Discharge Medications:   Current Discharge Medication List   START taking these medications   Details enoxaparin (LOVENOX) 40 mg/0.4 mL injection Administer 0.4 mL subcutaneously Twice a day for 7 days. Refills: 0   Associated Diagnoses: COVID-19 virus infection     CONTINUE these medications which have NOT CHANGED   Details Famotidine 40 mg tablet Take 40 mg by mouth Once Daily.   levocetirizine (XYZAL) 5 mg tablet Take 5 mg by mouth At bedtime.   pantoprazole (PROTONIX) 40 mg DR tablet Take 40 mg by mouth Once Daily.   aspirin 81 mg chewable tablet Take 81 mg by mouth Daily.   oxymetazoline (AFRIN) 0.05 % nasal spray Spray 2 Sprays in nose Twice a day. Takes mucinex nasal spray   calcium-cholecalciferol (CALCARB+D) 600 mg(1,500mg) -200 unit tablet Take 2 Tabs by mouth Daily.   multivitamin,tx-minerals (THERAGRAN M) Take 1 Tab by mouth Daily.   amLODIPine (NORVASC) 5 mg tablet Take 5 mg by mouth Daily.   Benazepril 20 mg tablet Take 20 mg by mouth Twice a day.   chlorpheniramine (CHLOR-TRIMETRON) 4 mg tablet Take 4 mg by mouth Every 6 hours as needed.   fluticasone-salmeterol (ADVAIR) 250-50 mcg/Dose inhaler Take 1 Puff by inhalation Twice a day.     STOP taking these medications     potassium chloride (KLOR-CON) 10 mEq tab Comments:  Reason for Stopping:        ondansetron HCL (ZOFRAN) 4 mg tablet Comments:  Reason for Stopping:        traMADoL (ULTRAM) 50 mg tablet Comments:  Reason for Stopping:
This spontaneous report as received from a registered nurse refers to an unspecified number of patients of unknown age and gender. There was no information about the patients, concurrent conditions, concomitant therapies or medical histories provided. On unknown dates, the patients were vaccinated with improperly stored doses of GARDASIL 9 lot # M024261 (expiry date: 30-JUL-2018), M017983 (expiry date: 30-MAY-2018), M011840 (expiry date 01-FEB-2018) (dose and route of administration were not reported). There was no adverse effect reported. Administered doses of vaccines underwent the temperature excursion of 0-2 degrees Celsius for 3 hours, which was detected by a data logger. There were no previous excursions reported. This is one of several reports received from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1701USA001650.
Information has been received from a healthcare business professional via a company representative referring to a 63 year old female patient. Information about pertinent medical history, concurrent conditions, concomitant medication and drug reactions/allergies was not provided. On an unknown date, the patient was vaccinated with PNEUMOVAX 23 (dose, strength, route, lot # and expiration date unknown) for prophylaxis. On an unspecified date after receiving PNEUMOVAX 23, the patient was seen by unspecified immunologist on unspecified date after receiving PNEUMOVAX 23. The patient was "diagnosed with low immune response" on unspecified date. The outcome for low immune response was not provided. The causality between low immune response and PNEUMOVAX 23 was unknown.